close

Urologix, Inc. operates as a medical device company that engages in developing, manufacturing, and marketing non-surgical therapies to treat benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. The company's patented cooling technology, ability to treat obstruction, and the results set it apart from other minimally invasive therapies. Its core product is the Targis System, consisting of a Control Unit [sold under the Targis and CoolWave names], and a Microwave Catheter Procedure Kit [sold under the Cooled ThermoCath (CTC), CTC Advance, and Targis names]. These products deliver the company's Cooled ThermoTherapy procedure, a branded transurethral microwave thermotherapy (TUMT) treatment, systematically. Its Cooled ThermoTherapy procedure relieves symptoms and obstruction of BPH by reducing enlarged prostate tissue. This system also allows physicians to customize treatment for individual patients through variable energy settings, while managing patient comfort. Urologix, Inc. sells its products to urologists through a mix of direct sales representatives and independent distributors in the United States and internationally. The company was founded in 1991 and is based in Minneapolis, Minnesota.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.27
Volume	1374
Volume Avg	23932
52 Week High	1.71
52 Week Low	0.55
PE	N/A
PE (group average)	39
EPS Year	-0.33
EPS change Q/Q	-40%
EPS change Q/Q Yr ago	-75%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-19.05%
REV change Q/Q	-9.09%
REV change Q/Q Yr ago	-16.67%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%